Literature DB >> 15585776

Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism.

S Jill James1, Paul Cutler, Stepan Melnyk, Stefanie Jernigan, Laurette Janak, David W Gaylor, James A Neubrander.   

Abstract

BACKGROUND: Autism is a complex neurodevelopmental disorder that usually presents in early childhood and that is thought to be influenced by genetic and environmental factors. Although abnormal metabolism of methionine and homocysteine has been associated with other neurologic diseases, these pathways have not been evaluated in persons with autism.
OBJECTIVE: The purpose of this study was to evaluate plasma concentrations of metabolites in the methionine transmethylation and transsulfuration pathways in children diagnosed with autism.
DESIGN: Plasma concentrations of methionine, S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH), adenosine, homocysteine, cystathionine, cysteine, and oxidized and reduced glutathione were measured in 20 children with autism and in 33 control children. On the basis of the abnormal metabolic profile, a targeted nutritional intervention trial with folinic acid, betaine, and methylcobalamin was initiated in a subset of the autistic children.
RESULTS: Relative to the control children, the children with autism had significantly lower baseline plasma concentrations of methionine, SAM, homocysteine, cystathionine, cysteine, and total glutathione and significantly higher concentrations of SAH, adenosine, and oxidized glutathione. This metabolic profile is consistent with impaired capacity for methylation (significantly lower ratio of SAM to SAH) and increased oxidative stress (significantly lower redox ratio of reduced glutathione to oxidized glutathione) in children with autism. The intervention trial was effective in normalizing the metabolic imbalance in the autistic children.
CONCLUSIONS: An increased vulnerability to oxidative stress and a decreased capacity for methylation may contribute to the development and clinical manifestation of autism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15585776     DOI: 10.1093/ajcn/80.6.1611

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  261 in total

1.  Impact of folic acid intake during pregnancy on genomic imprinting of IGF2/H19 and 1-carbon metabolism.

Authors:  Aggeliki Tserga; Alexandra M Binder; Karin B Michels
Journal:  FASEB J       Date:  2017-08-04       Impact factor: 5.191

2.  Liposomal-glutathione provides maintenance of intracellular glutathione and neuroprotection in mesencephalic neuronal cells.

Authors:  Gail D Zeevalk; Laura P Bernard; F T Guilford
Journal:  Neurochem Res       Date:  2010-06-10       Impact factor: 3.996

3.  Autism, imprinting and epigenetic disorders: a metabolic syndrome linked to anomalies in homocysteine recycling starting in early life??

Authors:  Yves Ménézo; Pierre Mares; Marc Cohen; Michel Brack; Stephane Viville; Kay Elder
Journal:  J Assist Reprod Genet       Date:  2011-12       Impact factor: 3.412

Review 4.  Improving the prediction of response to therapy in autism.

Authors:  Stephen Bent; Robert L Hendren
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 5.  Tetrahydrobiopterin as a novel therapeutic intervention for autism.

Authors:  Richard E Frye; Lynne C Huffman; Glen R Elliott
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 6.  Complementary and alternative medicine in autism: an evidence-based approach to negotiating safe and efficacious interventions with families.

Authors:  R Scott Akins; Kathy Angkustsiri; Robin L Hansen
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 7.  Immune therapy in autism: historical experience and future directions with immunomodulatory therapy.

Authors:  Michael G Chez; Natalie Guido-Estrada
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

8.  The "Gln-Type" Thiol Dioxygenase from Azotobacter vinelandii is a 3-Mercaptopropionic Acid Dioxygenase.

Authors:  Brad S Pierce; Bishnu P Subedi; Sinjinee Sardar; Joshua K Crowell
Journal:  Biochemistry       Date:  2015-12-17       Impact factor: 3.162

Review 9.  Developmental neurotoxicity - challenges in the 21st century and in vitro opportunities.

Authors:  Lena Smirnova; Helena T Hogberg; Marcel Leist; Thomas Hartung
Journal:  ALTEX       Date:  2014       Impact factor: 6.043

Review 10.  Understanding and determining the etiology of autism.

Authors:  Salvatore A Currenti
Journal:  Cell Mol Neurobiol       Date:  2009-09-23       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.